Revenue segments as reported by the company.

Life Sciences Solutions

Analytical Instruments

Specialty Diagnostics

Laboratory Products and Services

Eliminations

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Amortization of acquisition-related intangible assets

Research and development

Restructuring and other costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Thermo Fisher Scientific

Life Technologies was a biotech company founded in November 2008 through a US$6.7 billion merger of Invitrogen Corporation and Applied Biosystems Inc. The joint sales of the combined companies were about $3.5 billion; they had about 9,500 employees, and owned more than 3,600 licenses and patents.

Life Technologies

Thermo Fisher Scientific, Inc. engages in the provision of analytical instruments, equipment, reagents and consumables, software, and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. The Life Sciences Solutions segment is composed of a portfolio of reagents, instruments, and consumables used in biological and medical research, discovery and production of new drugs and vaccines, as well as diagnosis of infection and disease. The Analytical Instruments segment offers instruments, consumables, software, and services that are used for a range of applications in the laboratory, on the production line, and in the field. The Specialty Diagnostics segment provides diagnostic test kits, reagents, culture media, instruments, and associated products used to increase the speed and accuracy of diagnoses. The Laboratory Products and Services segment is involved in providing everything needed for the laboratory, including a combination of self-manufactured and sourced products for customers in research, academic, government, industrial, and healthcare settings. The company was founded on October 11, 1960 and is headquartered in Waltham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Thermo Fisher excels in 2022, eyes growth amid challenges

Thermo Fisher Scientific delivered exceptional 2022 results with strong Q4 performance and robust full-year revenue. Growth strategy and segment strengths position the company well for continued success in 2023.
Challenges such as normalization of growth, margin influences, and market dynamics require strategic management. Opportunities in high-growth markets and next-gen technologies offer avenues for further expansion and value creation.
Maintaining a focus on innovation, sustainability, and operational efficiency will be key to navigating challenges and capitalizing on growth opportunities in 2023.
Overall, Thermo Fisher Scientific's solid financial performance, strategic focus, and market positioning set a positive trajectory for continued success and value creation in the coming year.

Thermo Fisher excels in Q1 despite COVID challenges, eyes growth

Thermo Fisher Scientific's Q1 2023 showcased resilience amid challenges, driven by innovation and strategic initiatives. While facing short-term headwinds, the company remains well-positioned for long-term growth through market opportunities and operational strengths.

Thermo Fisher faces market challenges, focuses on cost management and acquisitions

Thermo Fisher Scientific navigated a challenging macroeconomic environment in Q2 2023, with varied performance across end markets. The company is focused on managing costs, driving productivity, and pursuing strategic acquisitions to enhance capabilities. Despite challenges, Thermo Fisher remains committed to ESG priorities and market outperformance.

Thermo Fisher reports solid Q3 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q3 performance was solid, with revenue growth and strategic acquisitions driving market position strengthening.
While facing challenges like revenue impact in Q4 and customer caution, the company remains optimistic about industry outlook and growth opportunities.
The company's focus on innovation, ESG priorities, and operational efficiency positions it well for future growth and success.
Management's insights into 2024 outlook indicate a balanced approach to growth through strategic investments and operational improvements.

Thermo Fisher posts solid earnings, eyes growth amid market challenges

Thermo Fisher Scientific delivered strong financial performance in Q4 2023 and full-year 2023, driven by innovation and customer focus.
While facing challenges in certain segments and markets, the company remains optimistic about growth opportunities and market outpacing.
Strategic acquisitions, focus on sustainability, and operational excellence position Thermo Fisher for continued success in 2024 and beyond.
Guidance for 2024 indicates a focus on organic growth, stable segment margins, and a commitment to long-term market outperformance.

Thermo Fisher reports strong Q1 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q1 2024 earnings call highlighted strong financial performance driven by a proven growth strategy and disciplined capital deployment. While facing challenges in certain end markets and regulatory uncertainties, the company remains optimistic about future growth opportunities. Key strengths include innovation, strategic partnerships, and a focus on corporate social responsibility.

Thermo Fisher excels in Q2, raises 2024 guidance amid market challenges

Thermo Fisher Scientific's Q2 performance reflects resilience and strategic focus amidst market challenges. The company's emphasis on innovation, operational efficiency, and customer relationships positions it well for sustained growth. With a positive outlook for 2024 and a commitment to long-term success, Thermo Fisher remains a strong player in the industry.

Thermo Fisher excels in Q3 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q3 2024 earnings call showcased strong financial performance, strategic innovations, and growth opportunities.
While facing challenges in certain market segments, the company's focus on innovation, partnerships, and financial strength positions it well for future growth.
With raised EPS guidance and revenue expectations, Thermo Fisher is poised for continued success through market expansion and strategic initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CME Group

Newmont Mining

Northrop Grumman

Starbucks

Fed's rate cut will not only make cheaper funds available to businesses and stock market investors, but also U.S. dollar less expensive in the international market.

Can Fed Put Counter Potential Negative Q2 Earnings? 5 Picks

Abbott Labs

Amgen

Johnson & Johnson

Eli Lilly

Medtronic

Merck

Novartis

Pfizer

UnitedHealth Group

How big does a company's market cap need to be to make the top 10 list of healthcare stocks? $111 billion.

The 10 Biggest Healthcare Stocks

The Anatomical Pathology business of Thermo Fisher (TMO) belongs to its Specialty Diagnostics segment that serves customers across healthcare and clinical laboratories.

Thermo Fisher's Unit Sale May Not Ail Specialty Diagnostics

Agilent Technologies

Avantor Inc.

Danaher

Investing in the life sciences tool sector can be tricky, but according to the financial services firm Janney, the investing gain will be a result of finding the right secular trend in its own sector that comes from exposure to the production of biological therapeutics.

One Firm Sees Up to 45% Upside in Top Companies in Life Sciences Tools

Thermo Fisher (TMO) and Roper will carry on with their current long-term supply agreement.

Thermo Fisher Abandons Gatan Deal in Want of European Nod

Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the stock?

Why Is Thermo Fisher (TMO) Up 0.6% Since Last Earnings Report?

GlaxoSmithKline

The latest acquisition aligns with Thermo Fisher's (TMO) strategy of enhancing capabilities of its Pharma Services through the right balance of capital investment, and merger and acquisition.

Thermo Fisher Acquires GlaxoSmithKline's Drug Production Site

Thermo Fisher Scientific Inc. (TMO) has been struggling lately, but the selling pressure may be coming to an end soon.

Thermo Fisher Scientific Sees Hammer Chart Pattern: Time to Buy?

Thermo Fisher Scientific, Inc. (TMO) CEO Marc Casper on Q1 2019 Results - Earnings Call Transcript

Thermo Fisher (TMO) reports strong Laboratory Products and Services performance, flaunting robust global demand.

Thermo Fisher (TMO) Beats on Q1 Earnings, Raises '19 View

bluebird bio

Bristol-Myers

Celgene

CRISPR Therapeutics

Editas Medicine

Guardant Health Inc

Genomic Health

Gilead Sciences

Illumina

Myriad Genetics

Invitae

Spark Therapeutics

Pacific Biosciences of California

REGENXBIO

Roche Holding AG

These next-generation companies are working on game-changing ways to obtain and profit from genetic insight.

Top Gene-Sequencing Stocks for 2019

ABIOMED

TMO vs. ABMD: Which Stock Is the Better Value Option?

TMO or ABMD: Which Is the Better Value Stock Right Now?

Strong analytical instruments business, product portfolio expansion and prudent growth strategy are likely to support Thermo Fisher (TMO) in Q1.

Thermo Fisher (TMO) to Report Q1 Earnings: What's in Store?

Buy-ranked Thermo Fisher’s shares have outperformed the Zacks Medical Instruments industry in the past three months (+16.5% vs. +8.1%).

Top Analyst Reports for Thermo Fisher

Thermo Fisher Scientific was up 0.9% at $276.19 on Monday, with shares having hit all-time highs.

4- Stocks to Buy Where Fundamentals and Charts Both Look Strong

Thermo Fisher acquires gene therapy contract manufacturing development organization Brammer Bio for $1.7 billion in cash.

Thermo Fisher Makes Move In Gene Therapy Space To Help Services Business Unit

On closure of the acquisition deal, Brammer Bio will be integral to Thermo Fisher's (TMO) pharma services business within its Laboratory Products and Services wing.

Thermo Fisher to Buy Brammer Bio, Tightens Gene Therapy Grip

Medical technology behemoth Thermo Fisher Scientific is spending $1.7 billion in cash to take over cell and gene therapy company Brammer Bio.

Why Medtech Behemoth Thermo Fisher Is Buying Into Gene Therapy

Tencent, Kansas City Southern, and Thermo Fisher Scientific all have strengths that the Oracle of Omaha would admire.

Stocks Warren Buffett Would Love: Thermo Fisher

Amazon

Top Research Reports for Amazon, Berkshire Hathaway & Thermo Fisher

News for Thermo Fisher Scientific Stock (TMO)